Paweł Przewięźlikowski – Chief Executive Officer
Mr. Pawel Przewiezlikowski, co-founded Selvita in 2007 and is the Chief Executive Officer of the company, responsible for strategic management, business and corporate development. He is also the President of Supervisory Board at Ardigen and Chief Executive of BioCentrum, Selvita’s daughter companies.
Mr. Przewiezlikowski is a member of the Economic Council of the Malopolska (Krakow) region. He was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment, as well as, EY Entrepreneur of the Year 2015 award in the New Technologies/Innovation category in Poland.
From 1994 to 2007 he worked at Comarch, a Polish information technology company. As a management board member since 1996, he was responsible for the divisions offering solutions for the pharmaceutical, banking, manufacturing and services industries and took part in the organic transformation of a university spin-off to the largest organically grown IT company in Central and Eastern Europe, employing over 2 700 people in 20 countries. In 1999-2007 he was also the co-founder, the first CEO and then the Vice President of the Supervisory Board of Interia.pl, the third largest Internet portal in Poland.
Mr. Przewiezlikowski holds an MBA from the joint program of the Teesside University (United Kingdom) and Krakow School of Economics (Poland) as well as master degree in computer science from AGH Technical University in Krakow. He also studied IT at the Technical University in Berlin.
Krzysztof Brzózka – Executive Vice President, Chief Scientific Officer
Dr. Krzysztof Brzozka joined Selvita in 2007 as a specialist responsible for evaluation, due diligence and in-licensing of research projects. In 2009 he became a Project Manager of the first anticancer project initiated at Selvita and in subsequent years initiated further research projects, also in additional therapeutic indications. In January 2012 he was appointed to the position of Chief Scientific Officer and Member of the Management Board and is currently responsible for development of internal pipeline of novel, small molecule therapies across various indications.
Dr. Brzozka holds a PhD degree from Ludwig Maximilian University in Munich (Germany) and an MSc degree in Biotechnology, specializing in Molecular Biology, from the Jagiellonian University in Krakow (Poland). He also completed a two-year Executive MBA at Stockholm University School of Business and the Cracow University of Economics Business School. In the years 2003 – 2007, Dr. Brzozka conducted research at the Ludwig Maximilian University in the field of intracellular signaling, pathogen defense mechanisms leading to the immune system inhibition and the innate immune response.
Dr. Brzozka has a unique interdisciplinary expertise in development of projects in the preclinical phase, ranging from in silico studies, medical chemistry and, in vitro and in vivo molecular biology studies and toxicology.
Setareh Shamsili – Chief Medical Officer
Dr. Shamsili served as an independent industry consultant for a number of immuno-oncology companies in the U.S. and Europe, contributing to programs in various stages of development and therapeutic classes including small molecules, antibodies and cancer vaccines.
Her latest position was the interim CMO at AxImmune, a U.S.-based immuno-oncology company. She was the first Chief Medical Officer of Merus NV, where she brought two initial candidates to the clinic for development in acute myeloid leukemia and the treatment of solid tumors. During her tenure at Merus through 2016, Dr. Shamsili was instrumental in providing support for successful fundraising activities and establishing strategic alliances. From 2006-2012, Dr. Shamsili served as Global Medical Leader Oncology at Astellas Pharma Global Development.
Dr. Shamsili received her M.D. degree and board certification in Internal Medicine from the National University of Medical Sciences in Tehran, with a focus in oncology, and received her Ph.D. in Oncology from the international Erasmus Medical University in Rotterdam.
Bogusław Sieczkowski – Executive Vice President, Chief Operating Officer
Mr. Boguslaw Sieczkowski is a co-founder of Selvita and currently holds the position of the Executive Vice President, as well as the Chief Operating Officer.
Mr. Sieczkowski has over 10 years of experience in management. His career was initiated in the mid-90s supervising computerization of companies within Bahlsen group. Since 2000 as a board member of Comarch Internet Ventures S.A. he developed the first ASP Services platform in Poland. Till 2007, as a Vice President of Comarch S.A. he was in charge of the largest subsector (250 people) delivering product for leading scientific and finance institutions.
Mr. Sieczkowski was awarded Knight’s Cross of the Order of Polonia Restituta for his contributions to the development of Poland’s business environment.
He holds an MBA from joint programme of the University of Teesside (United Kingdom) and Krakow School of Economics (Poland), master degree in computer science from Jagiellonian University in Krakow as well as Project Management Professional certificate issued by Project Management Institute (United States).
Mirosława Zydroń – Member of the Management Board, Director of Chemistry Department
Dr Miroslawa Zydron joined Selvita in December 2009, and has been responsible for the formation and organization of the Chemistry Services Division, strategic development of the chemistry research services, presentation of the company’s offer and building relationships with international clients from the pharmaceutical, biotechnology, chemical and agrochemical environments, as well as overseeing the ongoing projects to ensure the highest quality of services.
Dr. Zydron gained her experience in project management, formation of research and development structures and management of R&D teams in international organizations both in the scientific environment and Pliva company (then: Barr Pharmaceuticals, TEVA), as Head of R&D Laboratory, overseeing analytical and preformulation activities at the stage of drug form development and packaging processes in pilot production in GMP environment.
Dr. Zydron graduated from the Silesian Technical University (Poland), with MSc and PhD Degree in chemistry. Her PhD Thesis gained distinction from Academy of Sciences, Committee of Analytical Chemistry, for the best doctoral thesis in the area of analytical chemistry in Poland in 2004 – 2005. In 2009, she completed a two-year MBA Program at the Rotterdam School of Management at Erasmus University in Rotterdam (Netherlands).
Miłosz Gruca – Member of the Management Board, Director of Biology Department
Dr. Milosz Gruca is a graduate of the Jagiellonian University, where he earned his MSc degree in Biotechnology with specialization in Molecular Biology, and a PhD degree in Biochemistry. He also completed a two-year Executive MBA at Stockholm University School of Business and the Cracow University of Economics Business School.
Since 2007 he has been associated with Selvita, responsible, among many other activities, for the introduction of complex biological and analytical services to the company’s offer. Being a Member of the Board at Selvita’s subsidiary company BioCentrum Ltd., Dr. Gruca was responsible for the strategic management of Analytical, Biochemistry, and Molecular Biology laboratories. He participated in the creation of the company’s preclinical services offer. As part of his duties he is responsible for creation of project teams and scientific and strategic leadership of interdisciplinary teams of researchers. In 2010 he took charge of the largest department in the Selvita Group – Department of Biological Research.
Edyta Jaworska – Member of the Management Board
Edyta Jaworska is a graduate of the University of Economics in Krakow, where she graduated with MSc in Economics and Post-graduate Studies Diploma in Finance Management. She also studied at the University of Southern Denmark in Odense. She also holds an MBA degree from Stockholm University and Krakow University of Economics joint program.
Mrs. Jaworska joined Selvita in 2012, starting as a Business Development Manager responsible for the sales and development of Selvita offer in selected Western European countries. In 2014, she was promoted to the position of Business Development Director, taking over management of a sales team responsible for sales & development of Selvita services offer in Western Europe, Israel and Japan. Subject to the promotion to the Management Board, she is now responsible for the development of Selvita integrated drug discovery services.
Before she joined Selvita, she has gained several years of experience in managerial positions in various healthcare companies including OneMed group and International Nephrology Centers.